Sandoz Group AG Logo

Sandoz Group AG

SDZ | SW

Overview

Corporate Details

ISIN(s):
CH1243598427 (+2 more)
LEI:
5493000JWK6XWFEUD320
Country:
Switzerland
Address:
Suurstoffi 14, 6343 Rotkreuz
Sector:
Health Care
Industry:
Health Care Providers & Services

Description

Sandoz operates in the attractive and growing global off-patent medicines market, which benefits from a growing and aging population, higher rates of chronic disease, increasing market adoption as healthcare systems and payors seek to reduce the cost of medicines, and a consistent supply of upcoming loss of exclusivities (LoEs) as patents for originator products expire. Together, these drivers are expected to support long-term growth in volumes that will more than offset anticipated erosion in price.

Social Media

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-01 02:00
Regulatory News Service
Sandoz further asserts leadership in biosimilars, breaking ground on new Sloven…
English 7.7 KB
2025-06-02 02:00
Regulatory News Service
Sandoz launches first and only interchangeable denosumab biosimilars in US, pro…
English 19.9 KB
2025-05-21 02:00
Regulatory News Service
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe …
English 10.8 KB
2025-03-05 01:00
Earnings Release
Sandoz reports strong FY 2024 results and Q4 2024 sales
English 83.1 KB
2025-02-24 01:00
Regulatory News Service
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new…
English 21.0 KB
2025-02-03 01:00
Board/Management Change
Francisco Ballester to retire; Peter Stenico appointed President Region Interna…
English 5.4 KB
2025-01-14 01:00
Earnings Release
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd An…
English 11.2 KB
2024-12-17 01:00
Inside Information Statement
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Ac…
English 7.6 KB
2024-11-15 01:00
Regulatory News Service
Sandoz receives European Commission approval for Afqlir® (aflibercept), further…
English 7.2 KB
2024-10-30 01:00
Earnings Release
Sandoz reports third-quarter and nine-month 2024 sales
English 32.6 KB
2024-08-12 02:00
Regulatory News Service
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthe…
English 9.9 KB
2024-08-08 02:00
Earnings Release
Sandoz reports second-quarter sales and half-year 2024 results
English 53.6 KB
2024-07-25 02:00
Regulatory News Service
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chro…
English 7.3 KB
2024-07-01 02:00
Regulatory News Service
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by S…
English 12.2 KB
2024-05-22 02:00
Regulatory News Service
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the firs…
English 9.5 KB

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-02 N/A Non-Executive member Buy None 251,343.62 CHF
2025-04-15 N/A Non-Executive member Buy None 270,000.00 CHF
2025-04-15 N/A Non-Executive member Buy None 260,000.00 CHF
2025-04-15 N/A Non-Executive member Buy None 230,000.00 CHF
2025-04-15 N/A Non-Executive member Buy None 202,500.00 CHF
2025-04-15 N/A Non-Executive member Buy None 187,500.00 CHF
2024-08-21 N/A Non-Executive member Buy None 429,855.85 CHF
2024-04-30 N/A Non-Executive member Buy None 130,000.00 CHF
2024-04-30 N/A Non-Executive member Buy None 115,000.00 CHF
2024-04-30 N/A Non-Executive member Buy None 62,500.00 CHF

Peer Companies